These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 2127368

  • 1. Opsonic and protective activity of five human IgM monoclonal antibodies reactive with lipopolysaccharide antigen of Pseudomonas aeruginosa.
    Collins MS, Ladehoff DK, Mehton NS, Noonan JS.
    FEMS Microbiol Immunol; 1990 Dec; 2(5-6):263-8. PubMed ID: 2127368
    [Abstract] [Full Text] [Related]

  • 2. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.
    Horn MP, Zuercher AW, Imboden MA, Rudolf MP, Lazar H, Wu H, Hoiby N, Fas SC, Lang AB.
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2338-44. PubMed ID: 20308370
    [Abstract] [Full Text] [Related]

  • 3. Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.
    Hemachandra S, Kamboj K, Copfer J, Pier G, Green LL, Schreiber JR.
    Infect Immun; 2001 Apr; 69(4):2223-9. PubMed ID: 11254577
    [Abstract] [Full Text] [Related]

  • 4. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z, Kimmel R, Petersen S, Thomas S, Pier G, Bezabeh B, Luo R, Schreiber JR.
    Vaccine; 2005 May 09; 23(25):3264-71. PubMed ID: 15837231
    [Abstract] [Full Text] [Related]

  • 5. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
    Preston MJ, Gerçeker AA, Koles NL, Pollack M, Pier GB.
    Invest Ophthalmol Vis Sci; 1997 Jun 09; 38(7):1418-25. PubMed ID: 9191605
    [Abstract] [Full Text] [Related]

  • 6. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
    Hatano K, Goldberg JB, Pier GB.
    Infect Immun; 1995 Jan 09; 63(1):21-6. PubMed ID: 7528730
    [Abstract] [Full Text] [Related]

  • 7. Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo.
    Kim KS, Kang JH, Cross AS, Kaufman B, Zollinger W, Sadoff J.
    J Infect Dis; 1988 Jan 09; 157(1):47-53. PubMed ID: 2447199
    [Abstract] [Full Text] [Related]

  • 8. Human monoclonal antibodies to Pseudomonas aeruginosa type-specific lipopolysaccharides, toxin A and Klebsiella capsular polysaccharides.
    Lang AB, Fürer E, Schürch U, Cross AS, Larrick JW, Cryz SJ.
    Dev Biol Stand; 1990 Jan 09; 71():121-6. PubMed ID: 1698165
    [Abstract] [Full Text] [Related]

  • 9. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
    Eichler I, Joris L, Hsu YP, Van Wye J, Bram R, Moss R.
    J Clin Invest; 1989 Dec 09; 84(6):1794-804. PubMed ID: 2512330
    [Abstract] [Full Text] [Related]

  • 10. In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.
    Pier GB, Thomas D, Small G, Siadak A, Zweerink H.
    Infect Immun; 1989 Jan 09; 57(1):174-9. PubMed ID: 2491835
    [Abstract] [Full Text] [Related]

  • 11. Functional properties of isotype-switched immunoglobulin M (IgM) and IgG monoclonal antibodies to Pseudomonas aeruginosa lipopolysaccharide.
    Pollack M, Koles NL, Preston MJ, Brown BJ, Pier GB.
    Infect Immun; 1995 Nov 09; 63(11):4481-8. PubMed ID: 7591089
    [Abstract] [Full Text] [Related]

  • 12. In vitro and in vivo functional activities of monoclonal antibodies reactive with Pseudomonas aeruginosa serogroup 6 lipopolysaccharides.
    Pollack M, Tao M, Akiyama M, Pier GB, Koles NL.
    Antibiot Chemother (1971); 1991 Nov 09; 44():163-71. PubMed ID: 1801635
    [No Abstract] [Full Text] [Related]

  • 13. Production and characterization of monoclonal antibodies against serotype strains of Pseudomonas aeruginosa.
    Lam JS, MacDonald LA, Lam MY, Duchesne LG, Southam GG.
    Infect Immun; 1987 May 09; 55(5):1051-7. PubMed ID: 2437030
    [Abstract] [Full Text] [Related]

  • 14. Monoclonal antibodies as probes to examine serotype-specific and cross-reactive epitopes of lipopolysaccharides from serotypes O2, O5, and O16 of Pseudomonas aeruginosa.
    Lam JS, Handelsman MY, Chivers TR, MacDonald LA.
    J Bacteriol; 1992 Apr 09; 174(7):2178-84. PubMed ID: 1372599
    [Abstract] [Full Text] [Related]

  • 15. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.
    Pier GB, Koles NL, Meluleni G, Hatano K, Pollack M.
    Infect Immun; 1994 Apr 09; 62(4):1137-43. PubMed ID: 8132318
    [Abstract] [Full Text] [Related]

  • 16. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients.
    Saravolatz LD, Markowitz N, Collins MS, Bogdanoff D, Pennington JE.
    J Infect Dis; 1991 Oct 09; 164(4):803-6. PubMed ID: 1910070
    [Abstract] [Full Text] [Related]

  • 17. Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime.
    Akiyama M, Oishi K, Tao M, Matsumoto K, Pollack M.
    Microbiol Immunol; 2000 Oct 09; 44(8):629-35. PubMed ID: 11021392
    [Abstract] [Full Text] [Related]

  • 18. Establishment of stable cell lines producing anti-Pseudomonas aeruginosa monoclonal antibodies and their protective effects for the infection in mice.
    O'Oka H, Chonan E, Mizutani K, Fukuda T, Kuroiwa Y, Ono Y, Shigeta S.
    Microbiol Immunol; 1992 Oct 09; 36(12):1305-16. PubMed ID: 1287405
    [Abstract] [Full Text] [Related]

  • 19. Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity.
    Oishi K, Koles NL, Guelde G, Pollack M.
    J Infect Dis; 1992 Jan 09; 165(1):34-45. PubMed ID: 1727896
    [Abstract] [Full Text] [Related]

  • 20. Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide.
    Stoll BJ, Pollack M, Young LS, Koles N, Gascon R, Pier GB.
    Infect Immun; 1986 Sep 09; 53(3):656-62. PubMed ID: 2427453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.